Referências

1. 2006 report on the global AIDS epidemic: executive summary/UNAIDS.
2. Sherman K.E., Peters M., Koziel M.J., HIV and liver disease forum: conference proceedings, Hepatology, 45, pp. 1566-1577, (2007)
3. Bica I., McGovern B., Dhar R., Et al., Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection, Clin Infect Dis, 32, pp. 492-497, (2001)
4. Weber R., Sabin C.A., Friis-Moller N., Et al., Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study, Arch Intern Med, 166, pp. 1632-1641, (2006)
5. Ofotokun I., Smithson S.E., Lu C., Et al., Liver enzymes elevation and immune reconstitution among treatment-naive HIV-infected patients instituting antiretroviral therapy, Am J Med Sci, 334, pp. 334-341, (2007)
6. Akhtar M.A., Mathieson K., Arey B., Et al., Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis, Eur J Gastroenterol Hepatol, 20, pp. 1194-1204, (2008)
7. Housset C., Lamas E., Brechot C., Detection of HIV1 RNA and p24 antigen in HIV1-infected human liver, Res Virol, 141, pp. 153-159, (1990)
8. Li X.M., Jeffers L.J., Reddy K.R., Et al., Detection of HIV in liver tissue of AIDS patients by in situ hybridization, Hepatology, 10, (1989)
9. Quaresma J.A., Barros V.L., Pagliari C., Et al., Hepatocyte lesions and cellular immune response in yellow fever infection, Trans R Soc Trop Med Hyg, 101, pp. 161-168, (2007)
10. Amato V.S., de Andrade H.F., Duarte M.I., Mucosal leishmaniasis: in situ characterization of the host inflammatory response, before and after treatment, Acta Trop, 85, pp. 39-49, (2003)
11. Engwerda C.R., Kaye P.M., Organ-specific immune responses associated with infectious disease, Immunol Today, 21, pp. 73-78, (2000)
12. Carbone A., Gloghini A., Larocca L.M., Et al., Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells, Blood, 93, pp. 2319-2326, (1999)
13. Carbone A., Gloghini A., Serraino D., Et al., HIV-associated Hodgkin lymphoma, Curr Opin HIV AIDS, 4, pp. 3-10, (2009)
14. Raz E., Organ-specific regulation of innate immunity, Nat Immunol, 8, pp. 3-4, (2007)
15. Unanue E.R., Ito cells, stellate cells, and myofibroblasts: new actors in antigen presentation, Immunity, 26, pp. 9-10, (2007)
16. Cappell M.S., Schwartz M.S., Biempica L., Clinical utility of liver biopsy in patients with serum antibodies to the human immunodeficiency virus, Am J Med, 88, pp. 123-130, (1990)
17. Cavicchi M., Pialoux G., Carnot F., Et al., Value of liver biopsy for the rapid diagnosis of infection in human immunodeficiency virus-infected patients who have unexplained fever and elevated serum levels of alkaline phosphatase or gamma-glutamyl transferase, Clin Infect Dis, 20, pp. 606-610, (1995)
18. Prego V., Glatt A.E., Roy V., Et al., Comparative yield of blood culture for fungi and mycobacteria, liver biopsy, and bone marrow biopsy in the diagnosis of fever of undetermined origin in human immunodeficiency virus-infected patients, Arch Intern Med, 150, pp. 333-336, (1990)
19. Albrecht H., Redefining AIDS: towards a modification of the current AIDS case definition, Clin Infect Dis, 24, pp. 64-74, (1997)
20. Rouphael N.G., Talati N.J., Vaughan C., Et al., Infections associated with haemophagocytic syndrome, Lancet Infect Dis, 7, pp. 814-822, (2007)
21. Sun H.Y., Chen M.Y., Fang C.T., Et al., Hemophagocytic lymphohistiocytosis: an unusual initial presentation of acute HIV infection, J Acquir Immune Defic Syndr, 37, pp. 1539-1540, (2004)
22. Huang D.B., Wu J.J., Hamill R.J., Reactive hemophagocytosis associated with the initiation of highly active antiretroviral therapy (HAART) in a patient with AIDS, Scand J Infect Dis, 36, pp. 516-519, (2004)
23. Verbsky J.W., Grossman W.J., Hemophagocytic lymphohistiocytosis: diagnosis, pathophysiology, treatment, and future perspectives, Ann Med, 38, pp. 20-31, (2006)
24. Abdalian R., Heathcote E.J., Sclerosing cholangitis: a focus on secondary causes, Hepatology, 44, pp. 1063-1074, (2006)
25. Chen X.M., Keithly J.S., Paya C.V., Et al., Cryptosporidiosis, N Engl J Med, 346, pp. 1723-1731, (2002)
26. Benhamou Y., Caumes E., Gerosa Y., Et al., AIDS-related cholangiopathy. Critical analysis of a prospective series of 26 patients, Dig Dis Sci, 38, pp. 1113-1118, (1993)
27. Sterling R.K., Contos M.J., Smith P.G., Et al., Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection, Hepatology, 47, pp. 1118-1127, (2008)
28. Sherman K.E., Rouster S.D., Chung R.T., Et al., Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group, Clin Infect Dis, 34, pp. 831-837, (2002)
29. Benhamou Y., Bochet M., Di Martino V., Et al., Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group, Hepatology, 30, pp. 1054-1058, (1999)
30. Allory Y., Charlotte F., Benhamou Y., Et al., Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a case-control study. The MULTIVIRC group, Hum Pathol, 31, pp. 69-74, (2000)
31. Morishima C., Shuhart M.C., Yoshihara C.S., Et al., Preservation of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses despite global loss of CD4+ T cells in HCV/HIV coinfection, J Infect Dis, 196, pp. 577-586, (2007)
32. Benhamou Y., Di Martino V., Bochet M., Et al., Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy, Hepatology, 34, pp. 283-287, (2001)
33. Moreno A., Perez-Elias M.J., Quereda C., Et al., Syncytial giant cell hepatitis in human immunodeficiency virus-infected patients with chronic hepatitis C: 2 cases and review of the literature, Hum Pathol, 37, pp. 1344-1349, (2006)
34. Rosenberg P.M., Farrell J.J., Abraczinskas D.R., Et al., Rapidly progressive fibrosing cholestatic hepatitis-hepatitis C virus in HIV coinfection, Am J Gastroenterol, 97, pp. 478-483, (2002)
35. Thio C.L., Seaberg E.C., Skolasky R., Et al., HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS), Lancet, 360, pp. 1921-1926, (2002)
36. Salmon-Ceron D., Lewden C., Morlat P., Et al., Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol, J Hepatol, 42, pp. 799-805, (2005)
37. Soriano V., Puoti M., Bonacini M., Et al., Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel, AIDS, 19, pp. 221-240, (2005)
38. Kuppermann B.D., Petty J.G., Richman D.D., Et al., Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome, Am J Ophthalmol, 115, pp. 575-582, (1993)
39. Lucas S., Update on the pathology of AIDS, Intensive Crit Care Nurs, 17, pp. 155-166, (2001)
40. McCormack S., Walsh J.C., Barton S.E., Et al., Herpes simplex, Tratado de infectologia, pp. 547-565, (2004)
41. Quinnan G.V., Masur H., Rook A.H., Et al., Herpesvirus infections in the acquired immune deficiency syndrome, JAMA, 252, pp. 72-77, (1984)
42. Mastroianni A., Coronado O., Scarani P., Et al., Liver toxoplasmosis and acquired immunodeficiency syndrome, Recenti Prog Med, 87, pp. 353-355, (1996)
43. Denk H., Scheuer P.J., Baptista A., Et al., Guidelines for the diagnosis and interpretation of hepatic granulomas, Histopathology, 25, pp. 209-218, (1994)
44. Ishak K., Granulomas in the liver, Adv Pathol Lab Med, 8, (1995)
45. Lefkowitch J.H., Hepatic granulomas, J Hepatol, 30, pp. 40-45, (1999)
46. Kleiner D.E., Granulomas in the liver, Semin Diagn Pathol, 23, pp. 161-169, (2006)
47. Drebber U., Kasper H.U., Ratering J., Et al., Hepatic granulomas: histological and molecular pathological approach to differential diagnosis-a study of 442 cases, Liver Int, 28, pp. 828-834, (2008)
48. Gandhi N.R., Moll A., Sturm A.W., Et al., Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa, Lancet, 368, pp. 1575-1580, (2006)
49. Yew W.W., Leung C.C., Update in tuberculosis 2007, Am J Respir Crit Care Med, 177, pp. 479-485, (2008)
50. Riddell J.T., Kaul D.R., Karakousis P.C., Et al., Mycobacterium avium complex immune reconstitution inflammatory syndrome: long term outcomes, J Transl Med, 5, (2007)
51. Altamura M., Casale D., Pepe M., Et al., Immune responses to fungal infections and therapeutic implications, Curr Drug Targets Immune Endocr Metabol Disord, 1, pp. 189-197, (2001)
52. Wheat L.J., Small C.B., Disseminated histoplasmosis in the acquired immune deficiency syndrome, Arch Intern Med, 144, pp. 2147-2149, (1984)
53. Antinori S., Magni C., Nebuloni M., Et al., Histoplasmosis among human immunodeficiency virus-infected people in Europe: report of 4 cases and review of the literature, Medicine (Baltimore), 85, pp. 22-36, (2006)
54. Levitz S.M., The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis, Rev Infect Dis, 13, pp. 1163-1169, (1991)
55. Shibuya K., Hirata A., Omuta J., Et al., Granuloma and cryptococcosis, J Infect Chemother, 11, pp. 115-122, (2005)
56. Mortele K.J., Segatto E., Ros P.R., The infected liver: radiologic-pathologic correlation, Radiographics, 24, pp. 937-955, (2004)
57. Vanderveken O.M., Colebunders R.L., Collier I., Et al., Successful iterative drainage and partial hepatectomy for pyogenic liver abscess in a HIV seropositive patient, Acta Chir Belg, 102, pp. 59-62, (2002)
58. Wiwanitkit V., Causative agents of liver abscess in HIV-seropositive patients: a 10-year case series in Thai hospitalized patients, Trop Doct, 35, pp. 115-117, (2005)
59. Jones R., Dunning J., Nelson M., HIV and hepatitis C co-infection, Int J Clin Pract, 59, pp. 1082-1087, (2005)
60. Adinolfi L.E., Gambardella M., Andreana A., Et al., Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity, Hepatology, 33, pp. 1358-1364, (2001)
61. Estimated prevalence of significant liver disease among 4,052 HIV-infected adults with and without chronic hepatitis B and C [abstract 842], (2006)
62. Bonacini M., Louie S., Bzowej N., Et al., Survival in patients with HIV infection and viral hepatitis B or C: a cohort study, AIDS, 18, pp. 2039-2045, (2004)
63. Barreiro P., Martin-Carbonero L., Nunez M., Et al., Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3, Clin Infect Dis, 42, pp. 1032-1039, (2006)
64. Nunez M., Soriano V., Hepatotoxicity of antiretrovirals: incidence, mechanisms and management, Drug Saf, 28, pp. 53-66, (2005)
65. Maida I., Nunez M., Rios M.J., Et al., Severe liver disease associated with prolonged exposure to antiretroviral drugs, J Acquir Immune Defic Syndr, 42, pp. 177-182, (2006)
66. Tsokos M., Erbersdobler A., Pathology of peliosis, Forensic Sci Int, 149, pp. 25-33, (2005)
67. Yanoff M., Rawson A.J., Peliosis Hepatis. An anatomic study with demonstration of two varieties, Arch Pathol, 77, pp. 159-165, (1964)
68. Gulubova M., Immunohistochemical localization of collagen type III and type IV, laminin, tenascin and alpha-smooth muscle actin (alphaSMA) in the human liver in peliosis, Pathol Res Pract, 198, pp. 803-812, (2002)
69. Duarte M.I., Oliveira M.S., Lula D., Et al., Diagnóstico etiológico da angiomatose bacilar por reação imunohistoquímica, News Lab, 15, pp. 100-102, (1996)
70. Slater L.N., Pitha J.V., Herrera L., Et al., Rochalimaea henselae infection in acquired immunodeficiency syndrome causing inflammatory disease without angiomatosis or peliosis. Demonstration by immunocytochemistry and corroboration by DNA amplification, Arch Pathol Lab Med, 118, pp. 33-38, (1994)
71. Koehler J.E., Bartonella-associated infections in HIV-infected patients, AIDS Clin Care, 7, pp. 97-102, (1995)
72. Blumenfeld W., Egbert B.M., Sagebiel R.W., Differential diagnosis of Kaposi's sarcoma, Arch Pathol Lab Med, 109, pp. 123-127, (1985)
73. Cassidy W.M., Govindarajan S., Gupta S., Et al., Influence of HIV on chronic hepatitis B and D infection (abstract 485), Hepatology, 10, (1989)
74. Essex M., Kanki P.J., HIV-2, Textbook of AIDS Medicine, pp. 873-886, (1994)
75. Favre O., Heyraud J.P., Chossegros P., Et al., [Influence of HIV infection on hepatitis B virus infection in homosexual patients], Gastroenterol Clin Biol, 13, pp. 696-700, (1989)
76. Foster G.R., Ackrill A.M., Goldin R.D., Et al., Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA, Proc Natl Acad Sci U S A, 88, pp. 2888-2892, (1991)
77. Gallant J.E., Moore R.D., Richman D.D., Et al., Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group, J Infect Dis, 166, pp. 1223-1227, (1992)
78. Pinti M., Salomoni P., Cossarizza A., Anti-HIV drugs and the mitochondria, Biochim Biophys Acta, 1757, pp. 700-707, (2006)
79. Grulich A.E., van Leeuwen M.T., Falster M.O., Et al., Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis, Lancet, 370, pp. 59-67, (2007)
80. Grulich A.E., Li Y., McDonald A., Et al., Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis, AIDS, 16, pp. 1155-1161, (2002)
81. Angeletti P.C., Zhang L., Wood C., The viral etiology of AIDS-associated malignancies, Adv Pharmacol, 56, pp. 509-557, (2008)
82. Nasti G., Martellotta F., Berretta M., Et al., Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma, Cancer, 98, pp. 2440-2446, (2003)
83. Chang Y., Cesarman E., Pessin M.S., Et al., Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma, Science, 266, pp. 1865-1869, (1994)
84. Gallafent J.H., Buskin S.E., De Turk P.B., Et al., Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy, J Clin Oncol, 23, pp. 1253-1260, (2005)
85. Huang L.M., Chao M.F., Chen M.Y., Et al., Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1, J Biol Chem, 276, pp. 13427-13432, (2001)
86. Barillari G., Sgadari C., Fiorelli V., Et al., The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the α5β1 and αvβ3 integrins and by mobilizing sequestered basic fibroblast growth factor, Blood, 94, pp. 663-672, (1999)
87. Hengge U.R., Ruzicka T., Tyring S.K., Et al., Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy, Lancet Infect Dis, 2, pp. 281-292, (2002)
88. Ensoli B., Sgadari C., Barillari G., Et al., Biology of Kaposi's sarcoma, Eur J Cancer, 37, pp. 1251-1269, (2001)
89. Guedes F., de Andrade H.F., Fernandes E.R., Et al., The effects of human herpesvirus 8 infection and interferon-gamma response in cutaneous lesions of Kaposi sarcoma differ among human immunodeficiency virus-infected and uninfected individuals, Br J Dermatol, 159, pp. 839-846, (2008)
90. Feller L., Lemmer J., Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune reconstitution syndrome related Kaposi sarcoma, Infect Agent Cancer, 3, (2008)
91. Douglas J.L., Gustin J.K., Dezube B., Et al., Kaposi's sarcoma: a model of both malignancy and chronic inflammation, Panminerva Med, 49, pp. 119-138, (2007)
92. Ackerman A.B., Subtle clues to diagnosis by conventional microscopy. The patch stage of Kaposi's sarcoma, Am J Dermatopathol, 1, pp. 165-172, (1979)
93. Harris N.L., Jaffe E.S., Diebold J., Et al., World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997, J Clin Oncol, 17, pp. 3835-3849, (1999)
94. Carbone A., Gloghini A., AIDS-related lymphomas: from pathogenesis to pathology, Br J Haematol, 130, pp. 662-670, (2005)
95. Uccini S., Monardo F., Ruco L.P., Et al., High frequency of Epstein-Barr virus genome in HIV-positive patients with Hodgkin's disease, Lancet, 1, (1989)
96. Cioc A.M., Allen C., Kalmar J.R., Et al., Oral plasmablastic lymphomas in AIDS patients are associated with human herpesvirus 8, Am J Surg Pathol, 28, pp. 41-46, (2004)
97. Bozner P., Elkhalifa M.Y., Anaplastic large cell lymphoma of T-cell phenotype in acquired immunodeficiency syndrome, South Med J, 90, pp. 559-566, (1997)
98. Mounier N., Spina M., Gisselbrecht C., Modern management of non-Hodgkin lymphoma in HIV-infected patients, Br J Haematol, 136, pp. 685-698, (2007)
99. Levine A.M., Hodgkin's disease in the setting of human immunodeficiency virus infection, J Natl Cancer Inst Monogr, pp. 37-42, (1998)
100. Grogg K.L., Miller R.F., Dogan A., HIV infection and lymphoma, J Clin Pathol, 60, pp. 1365-1372, (2007)
101. Said J.W., Immunodeficiency-related Hodgkin lymphoma and its mimics, Adv Anat Pathol, 14, pp. 189-194, (2007)